Given the pharmacodynamic drawbacks of clopidogrel in patients with diabetes, which are potentially overcome with the newer, more potent P2Y12 inhibitors, the subgroup analyses of diabetic populations from phase III studies comparing prasugrel and ticagrelor versus clopidogrel in the setting of ACS are of particular interest. This evidence concerns the gene P2RY12 and diabetes mellitus.